{
    "info": {
        "nct_id": "NCT06507618",
        "official_title": "A Randomized, Phase III Trial of Pre-Operative Window of Endocrine Therapy to Inform Radiation Therapy Decisions in Older Women With Early-Stage Breast Cancer (POWER II)",
        "inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 65 Years",
        "exclusion_criteria": "* Bilateral synchronous breast cancer\n* Multicentric disease\n* Prior use of SERMS or aromatase inhibitors\n* History of ipsilateral breast radiation therapy\n* Has a known additional malignancy that is progressing and/or requires active treatment with cytotoxic chemotherapy or radiation therapy. Malignancies deemed stable and low risk for complication per investigator's judgment may be allowed after discussion with multi-site PI.\n* Current or planned use of a strong CYP2D6 inhibitor (e.g., Fluvoxamine, Paroxetine) and is not able to receive an endocrine therapy agent that does not use the CYP2D6 pathway.",
        "miscellaneous_criteria": "Inclusion Criteria (summary):\n\n* Diagnosis of ER+, PR +/-, and HER2- non amplified invasive breast cancer and clinically negative nodes\n* ECOG performance status 0-2\n* Females, aged ≥ 65 years\n* Patient is eligible for BCS and opted for BCS\n* Patient is a candidate for radiation therapy\n* Patient is a candidate for endocrine therapy (tamoxifen or an aromatase inhibitor)\n* Ability to take oral medication and be willing to adhere to endocrine therapy for the 3-month period prior to BCS\n* Agreement to adhere to Lifestyle Considerations (details in protocol) throughout study duration\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study"
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 65 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 65 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 65,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Multicentric disease",
            "criterions": [
                {
                    "exact_snippets": "Multicentric disease",
                    "criterion": "multicentric disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or planned use of a strong CYP2D6 inhibitor (e.g., Fluvoxamine, Paroxetine) and is not able to receive an endocrine therapy agent that does not use the CYP2D6 pathway.",
            "criterions": [
                {
                    "exact_snippets": "Current or planned use of a strong CYP2D6 inhibitor (e.g., Fluvoxamine, Paroxetine)",
                    "criterion": "use of strong CYP2D6 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "current or planned use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is not able to receive an endocrine therapy agent that does not use the CYP2D6 pathway",
                    "criterion": "ability to receive an endocrine therapy agent that does not use the CYP2D6 pathway",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known additional malignancy that is progressing and/or requires active treatment with cytotoxic chemotherapy or radiation therapy. Malignancies deemed stable and low risk for complication per investigator's judgment may be allowed after discussion with multi-site PI.",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy that is progressing and/or requires active treatment with cytotoxic chemotherapy or radiation therapy.",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requires active treatment with cytotoxic chemotherapy or radiation therapy",
                    "criterion": "additional malignancy treatment",
                    "requirements": [
                        {
                            "requirement_type": "active cytotoxic chemotherapy or radiation therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Malignancies deemed stable and low risk for complication per investigator's judgment may be allowed after discussion with multi-site PI.",
                    "criterion": "malignancy stability and risk",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "low risk for complication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior use of SERMS or aromatase inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Prior use of SERMS or aromatase inhibitors",
                    "criterion": "SERMS or aromatase inhibitors use",
                    "requirements": [
                        {
                            "requirement_type": "prior use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of ipsilateral breast radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "History of ipsilateral breast radiation therapy",
                    "criterion": "ipsilateral breast radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilateral synchronous breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Bilateral synchronous breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "laterality",
                            "expected_value": "bilateral"
                        },
                        {
                            "requirement_type": "synchrony",
                            "expected_value": "synchronous"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "* Females, aged ≥ 65 years",
            "criterions": [
                {
                    "exact_snippets": "Females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "aged ≥ 65 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 65,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of ER+, PR +/-, and HER2- non amplified invasive breast cancer and clinically negative nodes",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of ER+",
                    "criterion": "estrogen receptor (ER) status",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "PR +/-",
                    "criterion": "progesterone receptor (PR) status",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": [
                                "positive",
                                "negative"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2- non amplified",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "amplification",
                            "expected_value": "non amplified"
                        }
                    ]
                },
                {
                    "exact_snippets": "invasive breast cancer",
                    "criterion": "breast cancer type",
                    "requirements": [
                        {
                            "requirement_type": "invasiveness",
                            "expected_value": "invasive"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically negative nodes",
                    "criterion": "lymph node status",
                    "requirements": [
                        {
                            "requirement_type": "clinical status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provision of signed and dated informed consent form",
            "criterions": [
                {
                    "exact_snippets": "Provision of signed and dated informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stated willingness to comply with all study procedures and availability for the duration of the study",
            "criterions": [
                {
                    "exact_snippets": "Stated willingness to comply with all study procedures",
                    "criterion": "willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "availability for the duration of the study",
                    "criterion": "availability for the duration of the study",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status 0-2",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement to adhere to Lifestyle Considerations (details in protocol) throughout study duration",
            "criterions": [
                {
                    "exact_snippets": "Agreement to adhere to Lifestyle Considerations (details in protocol) throughout study duration",
                    "criterion": "adherence to Lifestyle Considerations",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "throughout study duration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is a candidate for endocrine therapy (tamoxifen or an aromatase inhibitor)",
            "criterions": [
                {
                    "exact_snippets": "Patient is a candidate for endocrine therapy (tamoxifen or an aromatase inhibitor)",
                    "criterion": "endocrine therapy candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy options",
                            "expected_value": [
                                "tamoxifen",
                                "aromatase inhibitor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is a candidate for radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "Patient is a candidate for radiation therapy",
                    "criterion": "radiation therapy candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to take oral medication and be willing to adhere to endocrine therapy for the 3-month period prior to BCS",
            "criterions": [
                {
                    "exact_snippets": "Ability to take oral medication",
                    "criterion": "oral medication administration",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing to adhere to endocrine therapy for the 3-month period prior to BCS",
                    "criterion": "adherence to endocrine therapy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "prior to BCS"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is eligible for BCS and opted for BCS",
            "criterions": [
                {
                    "exact_snippets": "Patient is eligible for BCS",
                    "criterion": "breast-conserving surgery (BCS) eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "opted for BCS",
                    "criterion": "breast-conserving surgery (BCS) choice",
                    "requirements": [
                        {
                            "requirement_type": "choice",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": [
        {
            "line": "Inclusion Criteria (summary):",
            "criterions": []
        }
    ]
}